Nymox Pharmaceutical Corp (NYMX.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Nymox Announces U.S. NDA For Fexapotide For BPH
- BRIEF-Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men
- BRIEF-Nymox Pharmaceutical posts qtrly loss $0.09/shr - SEC filing
- BRIEF-Nymox Pharmaceutical says European member states accepted MAA for fexapotide triflutate
- BRIEF-Nymox Pharmaceutical postpones September 16 AUA meeting